Copyright
©The Author(s) 2024.
World J Psychiatry. Nov 19, 2024; 14(11): 1735-1745
Published online Nov 19, 2024. doi: 10.5498/wjp.v14.i11.1735
Published online Nov 19, 2024. doi: 10.5498/wjp.v14.i11.1735
Table 1 Characteristics of the patients with schizophrenia (n = 3306)
| Variates | mean ± SD |
| Sex (male), n (%) | 1342 (40.6) |
| Age (years) | 34.5 ± 14.18 |
| Height (cm) | 165.6 ± 7.66 |
| Weight (kg) | 64.5 ± 12.44 |
| Duration of illness (month) | 89.1 ± 111.09 |
| Baseline BPRS total score | 48.8 ± 15.03 |
| Baseline BPRS factor scores | |
| Anxiety/depression | 9.8 ± 4.11 |
| Anergia | 10.2 ± 3.69 |
| Thought disturbance | 12.1 ± 4.30 |
| Activation | 6.7 ± 3.26 |
| Hostility/suspiciousness | 10.0 ± 3.89 |
- Citation: Xu BY, Jin K, Wu HS, Liu XJ, Wang XJ, Sang H, Li KQ, Sun MJ, Meng HQ, Deng HL, Xun ZY, Yang XD, Zhang L, Li GJ, Zhang RL, Cai DF, Liu JH, Zhao GJ, Liu LF, Wang G, Zhao CL, Guo B, Jin SC, Huang LY, Yang FD, Zheng JM, Zhan GL, Fang MS, Meng XJ, Zhang GY, Li HM, Liu XL, Li JH, Wu B, Li HY, Chen JD. Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia. World J Psychiatry 2024; 14(11): 1735-1745
- URL: https://www.wjgnet.com/2220-3206/full/v14/i11/1735.htm
- DOI: https://dx.doi.org/10.5498/wjp.v14.i11.1735